uniQure N.V. Investors Warned of Securities Fraud Lawsuit

UniQure N.V., a company listed on the NASDAQ as QURE, is facing a securities fraud class action lawsuit as per an announcement by Kirby McInerney LLP, a legal firm based in New York. Investors who bought uniQure securities between September 24, 2025, and October 31, 2025, are encouraged to seek legal advice to protect their interests. The crux of the lawsuit lies in the allegations that uniQure’s Pivotal Study design and comparison to the ENROLL-HD data set were not sanctioned by the FDA. Additionally, the company is accused of downplaying the possibility of delays in its Biologics License Application (BLA) submission despite claiming successful results from the Pivotal Study.

On November 3, 2025, uniQure disclosed that the FDA no longer agreed with the methodology used to compare the Phase I/II studies of AMT-130 to an external control data set as planned. This new development brought uncertainty to the timeline for submission of uniQure’s BLA. Subsequently, the price of uniQure shares plummeted by almost 50% from $67.69 per share on October 31, 2025, to $34.29 on November 3, 2025.

Investors who suffered losses due to this stock price drop are advised to reach out to Kirby McInerney LLP to discuss their situation and seek potential redress. Lead plaintiff applications must be filed before April 13, 2026, as applications submitted after this date may not be considered by the courts. The lead plaintiff plays a crucial role in representing the class and influencing key decisions in the lawsuit.

Investors who have pertinent information relating to uniQure’s actions during the Class Period are urged to contact Kirby McInerney LLP for a no-cost consultation. The legal firm has a strong track record in securities litigation and has secured significant recoveries for shareholders in the past. More details about the firm and the case can be found on Kirby McInerney LLP’s official website.

It is essential to act promptly and safeguard your rights if you were affected by the alleged securities fraud involving uniQure N.V. By working with experienced securities litigation attorneys, investors have the opportunity to seek compensation for losses incurred due to potentially misleading information provided by the company.